Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been given an average recommendation of "Buy" by the seven analysts that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $12.14.

STRO has been the subject of several recent research reports. Truist Financial cut their target price on shares of Sutro Biopharma from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, August 16th. Piper Sandler reissued an "overweight" rating and set a $11.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Monday, September 16th.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently modified their holdings of the business. Gladius Capital Management LP purchased a new position in shares of Sutro Biopharma during the third quarter valued at $28,000. ProShare Advisors LLC grew its stake in Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company's stock valued at $48,000 after acquiring an additional 5,373 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Sutro Biopharma in the 1st quarter valued at about $92,000. Price T Rowe Associates Inc. MD lifted its position in shares of Sutro Biopharma by 24.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company's stock worth $102,000 after purchasing an additional 3,578 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Sutro Biopharma during the third quarter worth approximately $77,000. Hedge funds and other institutional investors own 96.99% of the company's stock.

Sutro Biopharma Stock Performance

NASDAQ STRO traded up $0.09 on Thursday, reaching $2.69. The company's stock had a trading volume of 574,483 shares, compared to its average volume of 816,993. The firm's 50 day moving average is $3.48 and its two-hundred day moving average is $3.75. The stock has a market cap of $221.81 million, a PE ratio of -1.67 and a beta of 1.17. Sutro Biopharma has a twelve month low of $2.25 and a twelve month high of $6.13.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.